Advertisement
Advertisement
CAPR
Capricor Therapeutics Inc
24.74
USDSponsored
+1.71
+7.44%
Feb 06, 16:00 UTC -5
Closed
After-Market
24.80
+0.06
+0.25%
CAPR Earnings Reports
Positive Surprise Ratio
CAPR beat 22 of 37 last estimates.
59%
Next Report
Date of Next Report
Mar 17, 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/-$0.55
Implied change from Q3 25 (Revenue/ EPS)
--
/+1.85%
Implied change from Q4 24 (Revenue/ EPS)
-100.00%
/+243.75%
Capricor Therapeutics Inc earnings per share and revenue
On Nov 10, 2025, CAPR reported earnings of -0.54 USD per share (EPS) for Q3 25, beating the estimate of -0.55 USD, resulting in a 3.31% surprise. Revenue reached --, compared to an expected 544.00 thousand, with a -100.00% difference. The market reacted with a +11.51% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 12 analysts forecast an EPS of -0.55 USD, with revenue projected to reach -- USD, implying an increase of 1.85% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Phibro Animal Health Corporation Class A
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.68
Actual
$0.87
Surprise
+27.30%
Canopy Growth Corporation Common Shares
Report Date
Feb 06, 2026 For Q3 26
Estimate
-$0.04
Actual
-$0.13
Surprise
-198.00%
Aurora Cannabis Inc. Common Shares
Report Date
Feb 04, 2026 For Q3 26
Estimate
$0.21
Actual
$0.12
Surprise
-42.72%
High Tide Inc. Common Shares
Report Date
Jan 29, 2026 For Q4 25
Estimate
$0.00
Actual
-$0.56
Surprise
0.00%
Stryker Corporation
Report Date
Jan 29, 2026 For Q4 25
Estimate
$4.43
Actual
$4.47
Surprise
+0.69%
Boston Scientific Corp.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.78
Actual
$0.80
Surprise
+1.61%
ResMed Inc.
Report Date
Jan 29, 2026 For Q2 26
Estimate
$2.75
Actual
$2.81
Surprise
+2.15%
GE HealthCare Technologies Inc. Common Stock
Report Date
Feb 04, 2026 For Q4 25
Estimate
$1.42
Actual
$1.44
Surprise
+0.96%
Envista Holdings Corporation Common stock, $0.01 par value per share
Report Date
Feb 05, 2026 For Q4 25
Estimate
$0.32
Actual
$0.38
Surprise
+15.43%
Prestige Consumer Healthcare Inc.
Report Date
Feb 05, 2026 For Q3 26
Estimate
$1.15
Actual
$1.13
Surprise
-1.36%
FAQ
What were Capricor Therapeutics Inc's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Capricor Therapeutics Inc reported EPS of -$0.54, beating estimates by 3.31%, and revenue of $0.00, -100% below expectations.
How did the market react to Capricor Therapeutics Inc's Q3 2025 earnings?
The stock price moved up 11.51%, changed from $5.56 before the earnings release to $6.20 the day after.
When is Capricor Therapeutics Inc expected to report next?
The next earning report is scheduled for Mar 17, 2026.
What are the forecasts for Capricor Therapeutics Inc's next earnings report?
Based on 12
analysts, Capricor Therapeutics Inc is expected to report EPS of -$0.55 and revenue of -- for Q4 2025.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement